GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (NAS:SNGX) » Definitions » Shiller PE Ratio

SNGX (Soligenix) Shiller PE Ratio : (As of Apr. 11, 2025)


View and export this data going back to 1994. Start your Free Trial

What is Soligenix Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Soligenix Shiller PE Ratio Historical Data

The historical data trend for Soligenix's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Soligenix Shiller PE Ratio Chart

Soligenix Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Soligenix Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Soligenix's Shiller PE Ratio

For the Biotechnology subindustry, Soligenix's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Soligenix's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Soligenix's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Soligenix's Shiller PE Ratio falls into.


;
;

Soligenix Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Soligenix's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Soligenix's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-1.188/133.1571*133.1571
=-1.188

Current CPI (Dec. 2024) = 133.1571.

Soligenix Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -456.000 99.621 -609.506
201506 -360.000 100.684 -476.109
201509 -108.000 100.392 -143.249
201512 -177.600 99.792 -236.979
201603 -141.600 100.470 -187.668
201606 -45.600 101.688 -59.712
201609 -117.600 101.861 -153.732
201612 -33.600 101.863 -43.923
201703 -76.800 102.862 -99.419
201706 -98.400 103.349 -126.781
201709 -40.800 104.136 -52.171
201712 -64.800 104.011 -82.958
201803 -64.800 105.290 -81.951
201806 -43.200 106.317 -54.106
201809 -26.400 106.507 -33.006
201812 -43.200 105.998 -54.269
201903 -21.600 107.251 -26.818
201906 -28.800 108.070 -35.486
201909 -33.600 108.329 -41.301
201912 -33.600 108.420 -41.266
202003 -76.800 108.902 -93.906
202006 -24.000 108.767 -29.382
202009 -14.400 109.815 -17.461
202012 -45.600 109.897 -55.252
202103 -15.400 111.754 -18.349
202106 -12.000 114.631 -13.939
202109 -21.600 115.734 -24.852
202112 -19.536 117.630 -22.115
202203 -24.320 121.301 -26.697
202206 -13.280 125.017 -14.145
202209 -18.400 125.227 -19.565
202212 -20.960 125.222 -22.288
202303 -5.760 127.348 -6.023
202306 -3.560 128.729 -3.682
202309 -2.560 129.860 -2.625
202312 -2.610 129.419 -2.685
202403 -2.880 131.776 -2.910
202406 -1.310 132.554 -1.316
202409 -0.780 133.029 -0.781
202412 -1.188 133.157 -1.188

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Soligenix  (NAS:SNGX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Soligenix Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Soligenix's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Soligenix Business Description

Traded in Other Exchanges
Address
29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
Executives
Timothy R. Cote director 3529 TILDEN STREET, NW, WASHINGTON DC 20008
Richard Straube officer: CMO 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Christopher Schaber director, officer: Chairman, CEO and President 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Jonathan L. Guarino officer: Chief Financial Officer 100 WELLESLEY WAY, FREEHOLD NJ 07728
Oreola Donini officer: CSO 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Robert J. Rubin director 7901 SPRINGER ROAD, BETHESDA MD 20817
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Diane L. Parks director 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Mark E. Pearson director, 10 percent owner 3031 TISCH WAY, SUITE 505, SAN JOSE CA 95128
Preta Martina Cavazza other: Former 10% Owner VIA SUDAFRICA 20, ROME L6 00144
Enrico Cavazza other: Former 10% Owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Silvia Cavazza other: Former 10% Owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Francesca Cavazza other: Former 10% Owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Spa Essetifin 10 percent owner VIA SUDAFRICA 20, ROME L6 00144